MONDAY, July 7, 2025 (HealthDay News) — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Just in 2024 alone, respiratory syncytial virus (RSV) claimed 2,360 lives of children in hospitals notified in Bengaluru, Kolkata and Mumbai, said Dr Vasant M Khalatkar, National President of the ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness and proper prevention crucial. Recognising this urgent public health concern ...

While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants is Pfizer ’s PFE Abrysvo. Unlike Beyfortus and Enflonsia, which ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

The U.S. saw limited supply of antibody Beyfortus up to the 2023 RSV season, but the companies have since tripled production capacity and doubled the number of manufacturing sites.